Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nuevolution lands collaboration with Janssen
December 2015
SHARING OPTIONS:

COPENHAGEN, Denmark—Nuevolution A/S and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have established a multitarget collaboration using Nuevolution’s proprietary Chemetics drug discovery platform. The partners will focus on discovering and developing new medical entities for treating oncological, infectious and inflammatory diseases. Nuevolution will apply Chemetics to discover and advance drug candidates against targets of interest to Janssen. In return, Janssen will make an upfront payment to Nuevolution, as well as research funding and additional payments if specified research, development and commercial milestones are met. Nuevolution also stands to receive royalty payments on net sales of products resulting from this deal.
 
“We are excited about entering into the extensive collaboration with Janssen,” said Alex Gouliaev, CEO of Nuevolution. “We are looking forward to an excellent working relationship with their dedicated research and development teams.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.